Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Stephan Urban, PhD, developed a drug that blocks hepatitis B and D from entering liver cells.
The agency cited manufacturing concerns but did not question the safety and effectiveness of bulevirtide.
Cofounder and president Timothy M. Block will transition to executive chair of the foundation’s board of directors.
The new drug reduced HDV viral load and lowered liver enzyme levels in people with hepatitis B and D.
Hepatitis A and E usually resolve on their own, but hepatitis B and C can cause serious liver disease, including cirrhosis and liver cancer.
The link between COVID-19 and liver disease, along with research about NAFLD and NASH, topped the Hep treatment news this year.
Hepcludex, formerly known as Myrcludex B, suppressed hepatitis B and hepatitis D virus replication in clinical trials.
There are 5 viruses that cause viral hepatitis. A look at hepatitis A, B, C, D, and E.
The struggle of mother’s day for a son and mother affected by Hepatitis C and vertical transmission, and what the future looks like.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Lonafarnib and bulevirtide, when used with pegylated interferon, reduced hepatitis delta levels in two studies.
Information about the less-often discussed hepatitis virus, hepatitis D.
World Hepatitis Day is July 28, providing an opportunity for all of us to aid in the elimination of viral hepatitis.
Do you know your viral hepatitis alphabet? There are five designations for viral hepatitis: A, B, C, D, and E.
Beyond hepatitis A and C, taking a look at hepatitis B and D.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.